Mizuho raises Ventas stock price target to $98 on higher estimates

Mizuho raised Ventas’ price target to $98 from $94 and kept an Outperform rating, implying 11% upside from the current $88 share price. The firm lifted 2026/2027 FFO estimates to $3.92/$4.40 per share and AFFO estimates to $3.13/$3.56, while Ventas also beat Q1 EPS and revenue expectations at $0.12 and $1.66 billion. The company increased its ATM equity authorization to $3 billion and declared a $0.52 quarterly dividend payable July 16, 2026.

Analysis

The key signal here is not the higher target itself, but the combination of rising earnings assumptions and an expanded ATM capacity. That pairing implies management sees enough liquidity demand and equity tolerance to keep funding growth without stressing the balance sheet, which lowers the probability of a near-term capital crunch but also caps upside if the market starts pricing dilution faster than same-store cash flow growth. For a REIT trading near highs, the next leg likely depends less on headline beat-and-raise and more on whether SHOP operating leverage can keep compounding through 2026-27.

The second-order winner is the skilled nursing/senior housing ecosystem: if Ventas can sustain capital access at an elevated multiple, it becomes a more credible consolidator and capital allocator relative to smaller peers with weaker funding channels. That tends to widen the gap between large-cap healthcare REITs and sub-scale landlords, because the market will reward balance-sheet optionality over yield alone. The flip side is that every incremental equity issue raises the hurdle for total return, so any slowdown in occupancy or rent resets would be punished quickly.

The main contrarian point is that consensus may be underestimating how much of the move is already in the stock after a 40%+ run. Even with upward revisions, the implied upside from sell-side targets is modest, which means the name is now a quality compounder rather than a deep value rerating story. In this setup, the risk/reward shifts from outright long beta to relative value: if rates back up or defensive yield names de-rate, VTR can underperform despite good fundamentals, because the multiple already reflects optimism.

Key Decisions for Investors

• Hold VTR but trim into strength above the new target band: take partial profits on rallies toward $95-$98 over the next 1-2 months; upside from here is likely single-digit unless 2026 guidance moves higher again.
• Pair trade: long VTR / short weaker-capitalized healthcare REITs over 3-6 months; the edge is cheaper access to equity and better ability to fund growth, which should matter if acquisition activity re-accelerates.
• Sell cash-secured puts in VTR with 2-4 month tenor around 5-8% below spot if seeking income; risk/reward improves if the stock consolidates while fundamentals remain intact, but avoid if rates are trending higher.
• For event-driven exposure, wait for a post-earnings pullback before adding long VTR; the setup is better on dips because current valuation leaves limited margin of safety if AFFO growth merely meets rather than exceeds the upgraded estimates.